# Treatment Shortening of MDR-TB Using Existing and New Drugs

> **NCT02619994** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 214 (actual)

## Conditions studied

- Tuberculosis, Multidrug-Resistant

## Interventions

- **DRUG:** Linezolid
- **DRUG:** Delamanid
- **DRUG:** Levofloxacin
- **DRUG:** Pyrazinamide
- **DRUG:** Locally-used WHO-approved MDR-TB regimen in Korea

## Key facts

- **NCT ID:** NCT02619994
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2025-01-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02619994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02619994, "Treatment Shortening of MDR-TB Using Existing and New Drugs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02619994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*